Jazz Pharma director uses 1,706 shares for tax

Q: Was the JAZZ insider transaction a sale for investment purposes?

No. The filing states the 1,706 shares were sold or withheld to satisfy tax obligations from the vesting of restricted stock units, not an open-market sale initiated for investment reasons.

Q: How many JAZZ shares in total were used for tax withholding?

In total, 1,706 Ordinary Shares of Jazz Pharmaceuticals were disposed of on August 31, 2026 to pay tax liabilities related to the vesting of restricted stock units.

Q: Was a Rule 10b5-1 trading plan involved in this JAZZ Form 4?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, and the only footnote explains that shares were disposed of to satisfy tax obligations from vesting restricted stock units.

Q: What is the role of Mark Douglas Smith at Jazz Pharmaceuticals (JAZZ)?

Mark Douglas Smith is identified as a director of Jazz Pharmaceuticals plc in this Form 4 insider transaction report.

A Jazz Pharmaceuticals director had 1,706 shares withheld to satisfy taxes on vesting RSUs.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) reported that director Mark Douglas Smith had shares withheld on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 Ordinary Shares were disposed of through tax-withholding transactions at prices around the mid-$240s per share. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Tax Withholding: 1,706 shares

Tax Withholding 2 txns

Insider Smith Mark Douglas

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares ^F1	14	$244.6443	$3K
Tax Withholding	Ordinary Shares ^F1	1,692	$241.39	$408K

Holdings After Transaction: Ordinary Shares — 9,579 shares (Direct)

Footnotes (1)

F1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

Key Figures

Shares withheld for taxes (total): 1,706 shares Tax-withholding lot 1: 14 shares at $244.6443 per share Tax-withholding lot 2: 1,692 shares at $241.3900 per share

3 metrics

Shares withheld for taxes (total) 1,706 shares Ordinary Shares disposed of on August 31, 2026 to satisfy tax obligations from RSU vesting

Tax-withholding lot 1 14 shares at $244.6443 per share Ordinary Shares disposed of on August 31, 2026 for tax withholding

Tax-withholding lot 2 1,692 shares at $241.3900 per share Ordinary Shares disposed of on August 31, 2026 for tax withholding

Key Terms

restricted stock units, tax obligations, Ordinary Shares

3 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares sold to satisfy tax obligations arising out of the vesting"

Ordinary Shares financial

"transaction involved Jazz Pharmaceuticals plc Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did JAZZ report for Mark Douglas Smith?

Jazz Pharmaceuticals reported that director Mark Douglas Smith had 1,706 Ordinary Shares withheld on August 31, 2026 to satisfy tax obligations arising from the vesting of previously granted restricted stock units.

Was the JAZZ insider transaction a sale for investment purposes?

No. The filing states the 1,706 shares were sold or withheld to satisfy tax obligations from the vesting of restricted stock units, not an open-market sale initiated for investment reasons.

At what prices were the JAZZ shares used to pay taxes?

Two tax-withholding transactions occurred on August 31, 2026: 14 shares at $244.6443 per share and 1,692 shares at $241.3900 per share, all in Jazz Pharmaceuticals Ordinary Shares.

How many JAZZ shares in total were used for tax withholding?

In total, 1,706 Ordinary Shares of Jazz Pharmaceuticals were disposed of on August 31, 2026 to pay tax liabilities related to the vesting of restricted stock units.

Was a Rule 10b5-1 trading plan involved in this JAZZ Form 4?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, and the only footnote explains that shares were disposed of to satisfy tax obligations from vesting restricted stock units.

What is the role of Mark Douglas Smith at Jazz Pharmaceuticals (JAZZ)?

Mark Douglas Smith is identified as a director of Jazz Pharmaceuticals plc in this Form 4 insider transaction report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/02/2026 - 05:35 PM EDT Accepted by SEC EDGAR 09/02/2026 - 05:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Mark Douglas

(Last)

(First)

(Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City)

(State)

(Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	08/31/2026		F⁽¹⁾		14	D	$244.6443	11,271	D
Ordinary Shares	08/31/2026		F⁽¹⁾		1,692	D	$241.39	9,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

	By: /s/Paz Dizon, as attorney in fact For: Mark Douglas Smith	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR